Technology Innovation, People Centric
Endovastec™ is committed to provide trustworthy and universal access to state-of-the-art solutions of prolonging
and reshaping all lives, and to build a people centric enterprise ranking as a global leader of evolving and
emerging medical technologies through continuous innovation.
Endovastec™ is committed to R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices,
and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation,
drug coated PTA balloon catheters, and PTA balloon catheters etc.
Groundbreaking Ceremony for Endovastec™ Global Headquarters and Innovation & Industrialization Base Project Successfully Held
On October 17, 2022, the groundbreaking ceremony for the Global Headquarters and the Innovation & Industrialization Base Project of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”, stock code: 688016.SH) was successfully held in Shanghai International Medical Zone (SIMZ), Zhangjiang Science City, Pudong District of Shanghai.
17 Oct 2022
Endovastec™ Minos™ Abdominal Aortic Stent-Graft and Delivery System Receives Approval for Marketing in Colombia
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently received registration approval from the Colombian National Institute for Drug and Food Surveillance (INVIMA) for the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ System”). Colombia becomes the third Latin American country to approve the Minos™ System, after Brazil and Argentina. The Minos™ System obtained CE marking in 2019 and has been available in 12 overseas markets including Greece, Poland, the United Kingdom, Germany, Argentina, Brazil and other countries.
02 Sept 2022
Endovastec™ Announces 2022 Interim Results
Shanghai, China, 25 August 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) today announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the “Reporting Period”).
25 Aug 2022
Endovastec™ Presents Flagship Products at CICE 2022
Recently, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) held a seminar at the International Congress of Endovascular Surgery (Congresso International de Cirurgia Endovascular, CICE 2022) in Brazil, engaging local and global experts.
04 Jul 2022
Endovastec™ Castor™ Debuted at the First eCICE Conference in Brazil
São Paulo, Brazil, 30 October 2020 — The first virtual International Congress of Endovascular Surgery (eCongresso Internacional de Cirurgia Endovascular (eCICE)) kicked off as an online event from 7 – 8th September, 2020. As an influential conference in Latin America in the field of vascular surgery, the congress brought together vascular surgeons from around the world to showcase recent academic insights and developments in several cutting-edge application areas of endovascular treatment. Castor™ Branched Aortic Stent-Graft System (the “Castor™ Stent”), the world’s first stent system of the kind developed by Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), was launched on eCICE's live case demonstration.
19 Sept 2020
Endovastec™ Holds Virtual Launch Meeting for Fontus™ Branched Surgical Stent Graft System
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently hosted a product launch event titled “Elephant trunk for the heart: revival of the classic” for its Fontus™ Branched Surgical Stent Graft System (Fontus™), which was held back-to-back with a seminar on the stented elephant trunk procedure. Twenty-one experts from 17 hospitals gathered virtually to share clinical data and information related to the application of Fontus™, which attracted the attendance of over 5,000 viewers online.
28 Apr 2022